The weaker associations between plasma NGAL and risk of new-onset CKD in smoking participants and those with relatively higher baseline UAE may indicate that elevated NGAL levels due to such factors decrease their variation, and, thus, induce a loss of predictive performance regarding new-onset CKD. This evidence concerns the gene LCN2 and chronic kidney disease.